RIG-I, mAb (Alme-1)



ALX-804-849-C100	100 µg	417.00 USD

Product Specification

Alternative Name:	RIG-1, Retinoic acid-inducible gene 1 protein, DEAD-box protein 58, Probable ATP-dependent RNA helicase DDX58

Concentration:	1mg/ml

Purity Detail:	Protein G-affinity purified.

Purity:	≥95% (SDS-PAGE)

Formulation:	Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Clone:	Alme-1

Isotype:	Mouse IgG1

Immunogen:	Recombinant human RIG-I (retinoic acid-inducible gene 1 protein) (aa 201-713).

Source/Host:	Purified from concentrated hybridoma tissue culture supernatant.

Specificity:	Recognizes human and mouse RIG-I.

Application:	Immunohistochemistry (paraffin sections) Immunoprecipitation (1:200) Western blot (1:1’000)

Short Term Storage:	+4°C

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 1 year after receipt when stored at -20°C.

Handling:	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Miscellaneous/General:	RIG-I and MDA5 are highly conserved helicases involved in the innate immune response to virus. RIG-I is a member of the DEAD-box RNA helicases and is activated by cytoplasmic dsRNA and 5’-ppp RNA produced during the viral replication. The protein is characterized by a N-terminal region with two caspase recruitment domains (CARD) and a C-terminal region harboring potential ATP-dependent RNA helicase activity. RIG-1 recruits the CARD adaptor inducing IFN-β (Cardif) in a CARD-CARD-dependent manner resulting in NF-κB and IRF3 activation.

Figure 1: Western blot analysis of endogenous human RIG-I using RIG-I, mAb (Alme-1) (Prod. No. ALX-804-849). Method: Cell extracts (1x10⁵) from HEK 293T wild-type (lane 1) or transfected for 24 hours with a plasmid coding for human cardif to induce endogenous RIG-I (lane 2) were resolved by SDS-PAGE under reducing conditions, transferred to nitrocellulose and incubated with the RIG-I, mAb (Alme-1) (at 1:1’000 dilution) for 2 hours. Proteins were visualized using a peroxidase-conjugated polyclonal antibody to mouse IgG and a chemiluminescence detection system. Picture courtesy of Dr. Etienne Meylan, University of Lausanne.

Figure 2: Detection of human RIG-I in HeLa cells by Western Blot using RIG-I, mAb (Alme-1) (Prod. No. ALX-804-849) Method: Cell extracts from HeLa cells either unstimulated (lane 1) or stimulated for 6h (lane 2), 16h (lane 3) or 24h (lane 4) with interferon-γ were resolved by SDS-PAGE under reducing conditions, transferred to nitrocellulose and incubated with RIG-I, mAb (Alme-1) at a 1:1’000 dilution for 1 hour. Proteins were visualized using a peroxidase-conjugated polyclonal antibody to mouse IgG and a chemiluminescence detection system.

Figure 3: Immunohistochemical staining of endogenous human RIG-I in different human tissues (paraffin sections) using RIG-I, mAb (Alme-1) (Prod. No. ALX-804-849). Method: Different human normal tissues (A: Nasopharynx; B: Colon; C: Endometrium) or cancer tissues (D: Breast; E: Skin; F: Ovarian) were stained with RIG-I, mAb (Alme-1) by standard immunohistochemistry. Pictures courtesy of Human Protein Atlas (www.proteinatlas.org)

Please mouse over

Product Literature References

Phosphorylation-mediated negative regulation of RIG-I antiviral activity: M. U. Gack, et al.; J. Virol. 84, 3220 (2010), Abstract;

The antiviral adaptor proteins Cardif and Trif are processed and inactivated by caspases: M. Rebsamen, et al.; Cell Death Differ. 15, 1804 (2008), Abstract;